<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035334</url>
  </required_header>
  <id_info>
    <org_study_id>CL-503004</org_study_id>
    <nct_id>NCT00035334</nct_id>
    <nct_alias>NCT00017667</nct_alias>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis</brief_title>
  <official_title>A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Bellus Health Inc</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to
      placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical
      improvement/worsening of both renal and gastrointestinal functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AA amyloidosis is associated with chronic inflammatory conditions (rheumatoid arthritis,
      ankylosing spondylitis, inflammatory bowel disease), chronic infection (tuberculosis,
      osteomyelitis), and Familial Mediterranean Fever. Rheumatoid arthritis is the major cause of
      AA amyloidosis in Western Europe and North America. The most common clinical feature of AA
      amyloidosis is renal dysfunction manifested as nephrotic-range proteinuria or renal
      insufficiency at the time of diagnosis. End-stage renal failure is the cause of death in
      40-60% of cases. Gastrointestinal involvement is also frequent and is usually manifested as
      chronic diarrhea, body weight loss and malabsorption. Enlargement of the liver and spleen may
      also occur in some patients. The median survival time from diagnosis varies from 2 to 8 years
      depending on the stage of the disease at time of diagnosis. The goal of the current therapy
      in AA amyloidosis is the control of the associated disease. However, the current approaches
      for the treatment of AA amyloidosis are unspecific, toxic, invasive, and not sufficiently
      effective in many cases. NC-503 was specifically designed to compete with the naturally
      occurring sulfated GAGs for the binding to amyloidogenic precursor proteins, and to inhibit
      amyloid deposition into tissues. The proposed therapy with NC-503 is based on the prevention
      of the amyloid fibril formation. The objective of this clinical phase II/III study is to
      determine the efficacy and safety of NC-503 compared to a placebo in patients suffering from
      secondary (AA) amyloidosis by the assessment of clinical improvement/ worsening of both renal
      and gastrointestinal functions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>150</enrollment>
  <condition>Secondary (AA) Amyloidosis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Nephrotic Syndrome</condition>
  <condition>Familial Mediterranean Syndrome</condition>
  <condition>Kidney Diseases</condition>
  <condition>Gastrointestinal Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-503 (Anti-amyloidotic (AA) Agent)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL INCLUSION CRITERIA

          -  Patients must be 18 years of age or older.

          -  Males and females. If women of childbearing potential (i.e., not surgically sterilized
             or post-menopausal greater than one year) the patient must be using effective birth
             control.

          -  Diagnosis of AA amyloidosis demonstrated by positive biopsy (Congo red staining) and
             immunohistochemistry or immunoelectron microscopy at screening visit. Tissue from
             previous biopsy can be used for confirmation of diagnosis, if available.

          -  Persistent proteinuria defined as urinary protein excretion ? 1g/24h in two distinct
             24-h urine collections at least 1 week apart within 3 months prior to study entry
             (baseline, Month 0 visit) without evidence of urinary tract infection or overt heart
             failure (NYHA class III or more); OR creatinine clearance ? 60 mL/min in two distinct
             measures at least 1 week apart within 3 months prior to study entry (baseline, Month 0
             visit).

          -  Creatinine clearance ? 20 mL/min AND serum creatinine ? 3 mg/dl within 3 months prior
             to study entry (baseline, Month 0 visit).

          -  Written informed consent.

        PROTOCOL EXCLUSION CRITERIA

          -  Evidence or suspicion of renal or renovascular diseases other than renal AA
             amyloidosis.

          -  Presence of diabetes mellitus (Type I and II).

          -  Evidence of a cause of potentially reversible reduced renal function, such as
             accelerated hypertension or drug nephrotoxicity.

          -  AST, ALT, or ALP &gt; 5 times the upper limit of normal, or total bilirubin 50% above
             upper limits of normal.

          -  Presence of any other clinically significant diseases that could interfere with the
             interpretation of study results or compromise patient safety or any conditions that
             could reduce life expectancy to less than two years.

          -  Use of an investigational drug within thirty days prior to the screening visit.

          -  Active alcohol and/or drug abuse.

          -  Initiation of or any changes in ACE inhibitor therapy within 3 months prior to the
             screening visit.

          -  Initiation of or any changes in cytotoxic agents/colchicine therapy within 3 months
             prior to the screening visit.

          -  Inability to provide legal consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University School of Medicine, Department of Pathology and Laboratory Medicine,</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center, Renal Division</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatism Foundation Hospital</name>
      <address>
        <city>Heinola</city>
        <zip>FIN-18120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans, Service de Rhumatologie</name>
      <address>
        <city>Le Mans</city>
        <zip>CEDEX 1</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A</name>
      <address>
        <city>Lille</city>
        <zip>CEDEX 59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles</name>
      <address>
        <city>Paris</city>
        <zip>75679 CEDEX 14</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heller Institute of Medical Research, Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>2001</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen, Department of Medicine, Division of Rheumatology</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Reumatologiczny</name>
      <address>
        <city>Warszawa</city>
        <zip>02-632</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okregowy Szpital Kolejowy, Zaklad Reumatologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-137</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital No. 1</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>320102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat</name>
      <address>
        <city>Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cerrehpasa Tip Fakultesi</name>
      <address>
        <city>Askaray, Istanbul, Turkey</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology</name>
      <address>
        <city>Istanbul</city>
        <zip>34390 CAPA</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University Medical School Hospital, Department of Rheumatology</name>
      <address>
        <city>Uskudar, Altunizade, Istanbul</city>
        <zip>81190</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Scotland</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Safety, Tolerability and Pharmacokinetic Profile of FibrillexTM (Anti-AA Amyloid Agent) in Healthy and Renal Impaired Subjects. Garceau D., Gurbindo C., Laurin J. Neurochem Inc. Reference: Proceedings from the IXth International Symposium on Amyloidosis , 2001 (Budapest, Hungary)</citation>
  </reference>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2002</study_first_submitted>
  <study_first_submitted_qc>May 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2002</study_first_posted>
  <last_update_submitted>February 13, 2006</last_update_submitted>
  <last_update_submitted_qc>February 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2006</last_update_posted>
  <keyword>Familial Mediterranean Fever</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Secondary (AA) Amyloidosis</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

